The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients
Open accessAbstract
OBJECTIVE: In this study the safety and efficacy of imiquimod 5% cream for the treatments of actinic keratoses in kidney, heart and liver transplant recipients is evaluated. BACKGROUND: Growing populations of organ transplant recipients face increased risk of developing actinic keratosis (AK) and skin cancer secondary to continuous systemic immunosuppressive therapy. Imiquimod 5% cream is an effective option for the treatment of AK, but the safety of topical immune stimulation in immunocompromised patients has not been widely evaluated. METHODS: A total of 43 patients in six European transplant centres applied two sachets of topical imiquimod or vehicle cream three times per week to a 100 cm(2) field. Dosing continued for 16 weeks regardless of lesion clearance. Patients were assessed for safety variables that included adverse events, local skin reactions, laboratory results, vital signs, dosage of immunosuppressive medication and indication of graft rejection. A blinded independent expert committee was responsible for safety monitoring and final safety assessment. RESULTS: No graft rejections or trends for a deterioration of graft function were detected. No meaningful trends were observed in laboratory results. Among patients randomized to imiquimod, the complete clearance rate was 62.1% (18/29); for vehicle patients, the complete clearance rate was 0% (0/14). Clinical clearance was confirmed histologically in all cases. CONCLUSIONS: Imiquimod appears to be a safe alternative for the treatment of multiple actinic keratoses in patients with solid organ transplants. Efficacy was within the range previously observed in nontransplanted populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skin cancers after organ transplantation
Euvrard, S., Kanitakis, J., & Claudy, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022137 · Cited by 1,575
Self-citation
Cited by
The natural history of actinic keratosis: a systematic review
Werner, R. N., Sammain, A., Erdmann, R., Hartmann, V., Stockfleth, E., & Nast, A. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12420 · Cited by 369
Self-citationSkin Cancer in Organ Transplant Recipients—Where Do We Stand Today?
Ulrich, C., Kanitakis, J., Stockfleth, E., & Euvrard, S. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02386.x · Cited by 278
Self-citationWilley, A., Mehta, S., & Lee, P. K. (2010) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2009.01384.x · Cited by 124
Metadata
- Authors
- Ulrich, C., Bichel, J., Euvrard, S., Guidi, B., Proby, C. M., Van De Kerkhof, P. C. M., Amerio, P., Rønnevig, J., Slade, H. B., & Stockfleth, E.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-12-07
- Volume
- 157
- Pages
- 25-31
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2160221324
- Cited by
- 160
- References
- 1
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. https://app.cochat.ai/papers/10.1111/j.1365-2133.2007.08269.x
- The paper
- Ulrich, C., Bichel, J., Euvrard, S., Guidi, B., Proby, C. M., Van De Kerkhof, P. C. M., Amerio, P., Rønnevig, J., Slade, H. B., & Stockfleth, E. (2007). Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. British Journal of Dermatology. https://doi.org/10.1111/j.1365-2133.2007.08269.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.